Related Experiment Video
Updated: May 26, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease
Dana V Rizk1, Orlando Gutierrez, Emily B Levitan
1Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. drizk@uab.edu
Insights
Unrecognized myocardial infarctions (UMIs) are prevalent in chronic kidney disease (CKD) patients and significantly increase mortality risk. Early detection and management of UMIs in CKD are crucial for improving patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Epidemiology
Background:
- Unrecognized myocardial infarctions (UMIs) are common but understudied in chronic kidney disease (CKD).
- CKD affects myocardial infarction (MI) prevalence and prognosis.
- Understanding UMI in CKD is vital for patient care.
Purpose of the Study:
- To determine the prevalence of UMIs in adults with CKD.
- To assess the association between UMIs and mortality in CKD patients.
Main Methods:
- Utilized data from 18,864 participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.
- Defined UMIs using electrocardiogram (ECG) criteria in individuals without recognized MI.
- Assessed kidney function via estimated glomerular filtration rate (eGFR) and albuminuria; tracked all-cause mortality over median 4 years.
Main Results:
- UMI prevalence increased with declining eGFR and higher albuminuria levels.
- UMIs were associated with a 1.65-fold increased mortality risk in individuals with eGFR <60 mL/min/1.73 m(2).
- UMIs showed a 1.49-fold increased mortality risk in those with albuminuria ≥ 30 mg/g.
Conclusions:
- UMIs are common in individuals with reduced kidney function (eGFR <60 mL/min/1.73 m(2)) and albuminuria.
- UMIs are independently associated with increased all-cause mortality in the CKD population.
- Findings highlight the importance of considering UMIs in CKD patient risk stratification.
Background:
Unrecognized myocardial infarctions (UMIs) are common in the general population but have not been well studied in patients with chronic kidney disease (CKD). The purpose of this study was to determine the prevalence and prognosis for mortality of UMI among adults with CKD.
Methods:
The current study included 18 864 participants in the population-based REasons for Geographic And Racial Differences in Stroke (REGARDS) study who completed a baseline examination including a 12-lead electrocardiogram (ECG). UMI was defined as the presence of myocardial infarction (MI) by Minnesota ECG classification in the absence of self-reported or recognized MI (RMI). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation and albuminuria using albumin-to-creatinine ratio from a spot urine sample. All-cause mortality was assessed over a median 4 years of follow-up.
Results:
The prevalence of UMI was 4, 6, 6 and 13% among participants with eGFR levels of ≥ 60, 45-59.9, 30-44.9 and <30 mL/min/1.73 m(2), respectively, and 4, 5, 7 and 10% among participants with albuminuria levels of <10, 10-29.9, 30-299.9 and ≥ 300 mg/g, respectively. Compared to those with no MI, the multivariable adjusted hazard ratio for all-cause mortality associated with UMI and RMI was 1.65 [95% confidence interval (CI): 1.09-2.49] and 1.65 (95% CI: 1.20-2.26), respectively, among individuals with an eGFR <60 mL/min/1.73 m(2) and 1.49 (95% CI: 1.03-2.16) and 1.88 (95% CI: 1.40-2.52) among individuals with albuminuria ≥ 30 mg/g. Conclusion UMIs are common among individuals with an eGFR <60 mL/min/1.73 m(2) and albuminuria and associated with an increased mortality risk.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
